fda approved uses for glp 1 The New Weight Management Meds GIPR/GLP-1R dual agonist therapies for

Summary: Pancreatitis is a rare potential side effect of GLP-1 agonists, though large clinical trials show no definitive causal link and the absolute risk remains low

Injection Site Reactions: Many GLP-1 medications are administered via subcutaneous injection, which can lead to injection site reactions such as redness, itching, or swelling

Prescription DPP-4 inhibitors like sitagliptin extend GLP-1 half-life by blocking this enzyme, approximately doubling circulating GLP-1 levels

Patients taking semaglutide 7 mg and 14 mg doses only experienced an increase in heart rate by 1 bpm and 1.5 bpm respectively

Notably, GLP-1 receptor agonists also slow biliary motility, which can contribute to the development of bile ductblocking sludge and stones, resulting in acute pancreatitis

As the current guidelines have made this recommendation, other organizations and authors have also advocated for the use of these imaging techniques due to their relatively inexpensive and effective nature (Oprea et al